A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

Inclusion Criteria:

Stage IIIA/B/C/D or Stage IV melanoma and have histologically confirmed melanoma that is completely surgically resected (free of disease) with negative margins
Complete resection performed within 12 weeks prior to randomization or treatment assignment
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

Exclusion Criteria:

History of uveal or mucosal melanoma
Untreated/unresected CNS metastases or leptomeningeal metastases
Active, known or suspected autoimmune disease
Serious or uncontrolled medical disorder 4 weeks prior to screening
Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to randomization or treatment assignment. Participants with history of prior early stage basal/squamous cell skin cancer or non-invasive or in situ cancers that have undergone definitive treatment at any time are eligible
Prior immunotherapy treatments for any prior malignancies are not permitted

Other protocol-defined inclusion/exclusion criteria apply